BAX
Price
$42.71
Change
+$0.01 (+0.02%)
Updated
Mar 28, 6:59 PM EST
27 days until earnings call
GMED
Price
$53.65
Change
+$0.61 (+1.15%)
Updated
Mar 28, 6:59 PM EST
34 days until earnings call
Ad is loading...

Compare predictions BAX vs GMED

Header iconBAX vs GMED Comparison
Open Charts BAX vs GMEDBanner chart's image
Baxter International
Price$42.71
Change+$0.01 (+0.02%)
Volume$659.38K
CapitalizationN/A
Globus Medical
Price$53.65
Change+$0.61 (+1.15%)
Volume$203.99K
CapitalizationN/A
View a ticker or compare two or three
BAX vs GMED Comparison Chart

Loading...

BAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GMEDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
BAX vs. GMED commentary
Mar 29, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is BAX is a StrongSell and GMED is a StrongBuy.

COMPARISON
Comparison
Mar 29, 2024
Stock price -- (BAX: $42.74 vs. GMED: $53.64)
Brand notoriety: BAX and GMED are both not notable
Both companies represent the Medical Specialties industry
Current volume relative to the 65-day Moving Average: BAX: 102% vs. GMED: 68%
Market capitalization -- BAX: $21.77B vs. GMED: $7.26B
BAX [@Medical Specialties] is valued at $21.77B. GMED’s [@Medical Specialties] market capitalization is $7.26B. The market cap for tickers in the [@Medical Specialties] industry ranges from $3.82T to $0. The average market capitalization across the [@Medical Specialties] industry is $7.27B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

BAX’s FA Score shows that 3 FA rating(s) are green whileGMED’s FA Score has 1 green FA rating(s).

  • BAX’s FA Score: 3 green, 2 red.
  • GMED’s FA Score: 1 green, 4 red.
According to our system of comparison, BAX is a better buy in the long-term than GMED.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

BAX’s TA Score shows that 5 TA indicator(s) are bullish while GMED’s TA Score has 5 bullish TA indicator(s).

  • BAX’s TA Score: 5 bullish, 4 bearish.
  • GMED’s TA Score: 5 bullish, 6 bearish.
According to our system of comparison, BAX is a better buy in the short-term than GMED.

Price Growth

BAX (@Medical Specialties) experienced а +1.74% price change this week, while GMED (@Medical Specialties) price change was +2.90% for the same time period.

The average weekly price growth across all stocks in the @Medical Specialties industry was +0.84%. For the same industry, the average monthly price growth was -0.26%, and the average quarterly price growth was +4.27%.

Reported Earning Dates

BAX is expected to report earnings on Apr 25, 2024.

GMED is expected to report earnings on May 02, 2024.

Industries' Descriptions

@Medical Specialties (+0.84% weekly)

Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.

SUMMARIES
A.I.dvisor published
a Summary for BAX with price predictions.
OPEN
A.I.dvisor published
a Summary for GMED with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
BAX($21.8B) has a higher market cap than GMED($7.26B). BAX has higher P/E ratio than GMED: BAX (85.61) vs GMED (50.13). BAX YTD gains are higher at: 11.330 vs. GMED (0.657). BAX has higher annual earnings (EBITDA): 1.67B vs. GMED (347M). BAX has more cash in the bank: 3.19B vs. GMED (518M). GMED has less debt than BAX: GMED (520M) vs BAX (14.4B). BAX has higher revenues than GMED: BAX (14.8B) vs GMED (1.57B).
BAXGMEDBAX / GMED
Capitalization21.8B7.26B300%
EBITDA1.67B347M482%
Gain YTD11.3300.6571,725%
P/E Ratio85.6150.13171%
Revenue14.8B1.57B944%
Total Cash3.19B518M617%
Total Debt14.4B520M2,769%
FUNDAMENTALS RATINGS
BAX vs GMED: Fundamental Ratings
BAX
GMED
OUTLOOK RATING
1..100
6062
VALUATION
overvalued / fair valued / undervalued
1..100
5
Undervalued
79
Overvalued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
2586
PRICE GROWTH RATING
1..100
3358
P/E GROWTH RATING
1..100
4919
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

BAX's Valuation (5) in the Medical Specialties industry is significantly better than the same rating for GMED (79). This means that BAX’s stock grew significantly faster than GMED’s over the last 12 months.

GMED's Profit vs Risk Rating (75) in the Medical Specialties industry is in the same range as BAX (100). This means that GMED’s stock grew similarly to BAX’s over the last 12 months.

BAX's SMR Rating (25) in the Medical Specialties industry is somewhat better than the same rating for GMED (86). This means that BAX’s stock grew somewhat faster than GMED’s over the last 12 months.

BAX's Price Growth Rating (33) in the Medical Specialties industry is in the same range as GMED (58). This means that BAX’s stock grew similarly to GMED’s over the last 12 months.

GMED's P/E Growth Rating (19) in the Medical Specialties industry is in the same range as BAX (49). This means that GMED’s stock grew similarly to BAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
BAXGMED
RSI
ODDS (%)
Bearish Trend 1 day ago
67%
Bearish Trend 1 day ago
65%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
48%
Bullish Trend 1 day ago
74%
Momentum
ODDS (%)
Bullish Trend 1 day ago
55%
Bullish Trend 1 day ago
76%
MACD
ODDS (%)
Bearish Trend 1 day ago
59%
Bearish Trend 1 day ago
67%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
54%
Bullish Trend 1 day ago
69%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
55%
Bearish Trend 1 day ago
57%
Advances
ODDS (%)
Bullish Trend 1 day ago
51%
Bullish Trend 1 day ago
66%
Declines
ODDS (%)
Bearish Trend 4 days ago
52%
Bearish Trend 5 days ago
58%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
55%
Bullish Trend 1 day ago
69%
Aroon
ODDS (%)
Bullish Trend 1 day ago
59%
Bearish Trend 1 day ago
56%
View a ticker or compare two or three
Ad is loading...
BAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
GMEDDaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
IOBT1.750.02
+1.16%
IO Biotech
CYBR265.632.45
+0.93%
CyberArk Software Ltd
GTX9.94-0.09
-0.90%
Garrett Motion
CETX4.19-0.07
-1.64%
Cemtrex
CALT21.01-0.48
-2.22%
Calliditas Therapeutics AB

BAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, BAX has been loosely correlated with MDT. These tickers have moved in lockstep 57% of the time. This A.I.-generated data suggests there is some statistical probability that if BAX jumps, then MDT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To BAX
1D Price
Change %
BAX100%
+0.12%
MDT - BAX
57%
Loosely correlated
+0.26%
TFX - BAX
56%
Loosely correlated
+1.03%
ABT - BAX
54%
Loosely correlated
+0.16%
ZBH - BAX
53%
Loosely correlated
-0.48%
SILK - BAX
49%
Loosely correlated
-2.19%
More

GMED and

Correlation & Price change

A.I.dvisor indicates that over the last year, GMED has been loosely correlated with KIDS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if GMED jumps, then KIDS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To GMED
1D Price
Change %
GMED100%
+1.09%
KIDS - GMED
48%
Loosely correlated
+0.79%
IART - GMED
48%
Loosely correlated
+1.78%
IDXX - GMED
48%
Loosely correlated
+0.07%
ATEC - GMED
44%
Loosely correlated
-0.29%
TMO - GMED
43%
Loosely correlated
+0.32%
More